Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05DBY
|
||||
Former ID |
DIB002648
|
||||
Drug Name |
Imagabalin
|
||||
Synonyms |
Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Generalized anxiety disorder [ICD9: 300, 300.02, 311; ICD10:F32, F40-F42, F41.1] | Phase 3 | [531511] | ||
Company |
Pfizer Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C9H19NO2
|
||||
Canonical SMILES |
C(=O)(C[C@H](C[C@@H](CCC)C)N)O
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Voltage-dependent calcium channel subunit alpha-2/delta-1 | Target Info | Agonist | [528162], [531511] | |
PANTHER Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
References | |||||
Ref 528162 | Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. Epub 2006 Apr 26. | ||||
Ref 531511 | Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.